D.E. Shaw & Co
RNAC icon

D.E. Shaw & Co’s Cartesian Therapeutics RNAC Stock Holding History

D.E. Shaw & Co’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$299K Buy
+28,651
New +$212K ﹤0.01% 4415
2021
Q2 		– Sell
-2,379
Closed -$323K – 4979
2021
Q1 		$323K Sell
2,379
-4,087
-63% -$507K ﹤0.01% 3681
2020
Q4 		$588K Buy
+6,466
New +$561K ﹤0.01% 3312
2020
Q3 		– Sell
-4,196
Closed -$357K – 4107
2020
Q2 		$357K Buy
+4,196
New +$380K ﹤0.01% 3553
2019
Q2 		– Sell
-1,022
Closed -$73K – 3831
2019
Q1 		$73K Buy
+1,022
New +$64.8K ﹤0.01% 3501
2017
Q4 		– Sell
-409
Closed -$224K – 3715
2017
Q3 		$224K Buy
+409
New +$218K ﹤0.01% 3260

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co's RNAC Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in Cartesian Therapeutics (RNAC) in Q2 2026: 28,651 shares worth $299K. The stake represents ﹤0.01% of the portfolio and ranks #4415 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in RNAC as recently as Q1 2021.

D.E. Shaw & Co first reported a position in RNAC in Q3 2017 and has held it in 6 quarters since. The position peaked at $588K in Q4 2020. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • D.E. Shaw & Co held 28,651 shares of Cartesian Therapeutics worth $299K as of Q2 2026.
  • Cartesian Therapeutics was a new D.E. Shaw & Co position in Q2 2026.
  • Cartesian Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4415 holding.
  • D.E. Shaw & Co first reported a position in Cartesian Therapeutics in Q3 2017 and has held it in 6 quarters since.
  • D.E. Shaw & Co's Cartesian Therapeutics position peaked at $588K in Q4 2020.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.